

David Valcarcel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6581205/publications.pdf>

Version: 2024-02-01

161
papers

5,116
citations

93792

39
h-index

120465

65
g-index

168
all docs

168
docs citations

168
times ranked

6626
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. <i>Blood Advances</i> , 2022, 6, 774-784.	2.5	42
2	Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry. <i>Bone Marrow Transplantation</i> , 2022, 57, 1531-1538.	1.3	5
3	Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 53.e1-53.e8.	0.6	3
4	A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 86, 102505.	0.6	4
5	Ex vivo Tâ€cell depletion vs postâ€transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graftâ€vsâ€host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2021, 106, 114-125.	1.1	2
6	Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. <i>Leukemia and Lymphoma</i> , 2021, 62, 2288-2291.	0.6	1
7	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1426-1436.	0.8	49
8	Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6907.	1.8	10
9	Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. <i>Blood</i> , 2021, 138, 1429-1440.	0.6	54
10	Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?. <i>Bone Marrow Transplantation</i> , 2021, 56, 2489-2496.	1.3	15
11	Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2826-2833.	1.3	5
12	Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 2606-2606.	0.6	3
13	Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial. <i>Blood</i> , 2021, 138, 1517-1517.	0.6	1
14	Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2021, , 1-9.	0.6	0
15	Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. <i>Bone Marrow Transplantation</i> , 2020, 55, 641-648.	1.3	58
16	Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 605-622.	1.2	25
17	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 358-366.	2.0	36
18	Micronuclei, dmin chromosomes and MYC amplifications as a singular presentation of myeloid malignancies. <i>British Journal of Haematology</i> , 2020, 191, e19-e22.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1823-1832.	0.6	1
20	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
21	Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. <i>Leukemia</i> , 2020, 34, 3420-3425.	3.3	22
22	Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project). <i>Blood</i> , 2020, 136, 32-33.	0.6	0
23	Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
24	Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry. <i>Blood</i> , 2020, 136, 20-21.	0.6	1
25	Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy. <i>Blood</i> , 2020, 136, 27-29.	0.6	0
26	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
27	Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). <i>Blood</i> , 2020, 136, 14-16.	0.6	1
28	Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival. <i>Blood</i> , 2020, 136, 13-14.	0.6	0
29	Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. <i>British Journal of Haematology</i> , 2019, 184, 797-807.	1.2	13
30	Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group. <i>Advances in Hematology</i> , 2019, 2019, 1-11.	0.6	2
31	Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 2151-2162.	0.8	2
32	Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2019, 25, 6976-6985.	3.2	55
33	Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1825-1831.	2.0	34
34	Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms. <i>Clinical Cancer Research</i> , 2019, 25, 4616-4623.	3.2	13
35	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. <i>Journal of Clinical Oncology</i> , 2019, 37, 367-374.	0.8	110
36	Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). <i>European Journal of Haematology</i> , 2019, 102, 465-471.	1.1	18

#	ARTICLE	IF	CITATIONS
37	Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. <i>Scientific Reports</i> , 2019, 9, 16680.	1.6	15
38	Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1133-1137.	1.3	0
39	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1022-1030.	2.0	11
40	Donor lymphocyte infusion for BK virus hemorrhagic cystitis and nephropathy: a case report. <i>Bone Marrow Transplantation</i> , 2019, 54, 772-774.	1.3	4
41	Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2019, 60, 1522-1527.	0.6	2
42	Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30). <i>Blood</i> , 2019, 134, 3015-3015.	0.6	1
43	Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study. <i>Blood</i> , 2019, 134, 2361-2361.	0.6	8
44	Transcriptional Regulation of Hematopoietic Stem Cells in Aging and Myelodysplastic Syndrome Reveals DDIT3 As a Potential Driver of Transformation. <i>Blood</i> , 2019, 134, 3764-3764.	0.6	0
45	Registered Replication Report: Dijksterhuis and van Knippenberg (1998). <i>Perspectives on Psychological Science</i> , 2018, 13, 268-294.	5.2	46
46	CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 964-972.	2.0	19
47	Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. <i>Annals of Hematology</i> , 2018, 97, 1349-1356.	0.8	34
48	Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. <i>Experimental Hematology</i> , 2018, 62, 24-32.	0.2	15
49	Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin. <i>Transfusion</i> , 2018, 58, 2501-2505.	0.8	14
50	Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2018, 101, 407-414.	1.1	7
51	The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. <i>Leukemia Research</i> , 2018, 70, 34-36.	0.4	15
52	Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab. <i>Blood</i> , 2018, 132, 3402-3402.	0.6	1
53	Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. <i>Oncotarget</i> , 2018, 9, 19342-19355.	0.8	15
54	A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1177-1185.	2.0	22

#	ARTICLE	IF	CITATIONS
55	A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with $\geq 30\%$ blasts. <i>Leukemia</i> , 2017, 31, 2799-2806.	3.3	59
56	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 971-979.	2.0	16
57	Do Patients and Physicians Agree When They Assess Quality of Life?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1005-1010.	2.0	12
58	Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. <i>Experimental Hematology</i> , 2017, 48, 1-11.	0.2	54
59	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 372-380.	1.3	53
60	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. <i>Leukemia Research</i> , 2017, 63, 85-89.	0.4	9
61	Excess mortality in the myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2017, 92, 149-154.	2.0	15
62	Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 438-444.	1.3	7
63	Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. <i>Bone Marrow Transplantation</i> , 2017, 52, 107-113.	1.3	45
64	Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis. <i>Annals of Hematology</i> , 2017, 96, 317-318.	0.8	2
65	Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 491-497.	2.0	37
66	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/ II Trial. <i>Blood</i> , 2017, 130, 847-847.	0.6	8
67	Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. <i>Clinical Cancer Research</i> , 2016, 22, 5673-5681.	3.2	39
68	Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 33-38.	1.1	23
69	Imported Disease Screening Prior to Chemotherapy and Bone Marrow Transplantation for Oncohematological Malignancies. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1463-1468.	0.6	18
70	Cord Blood Units with High CD3 + Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell-Depleted Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1073-1079.	2.0	11
71	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	0.8	61
72	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. <i>BMC Hematology</i> , 2016, 16, 12.	2.6	31

#	ARTICLE	IF	CITATIONS
73	The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial). <i>Bone Marrow Transplantation</i> , 2016, 51, 1404-1407.	1.3	4
74	Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 584-588.	2.0	45
75	NiCord single unit expanded umbilical cord blood transplantation: Results of phase I/II trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7004-7004.	0.8	3
76	Isolate Loss of Y Chromosome Decreases the Risk of Leukemic Transformation in the Myelodysplastic Syndromes. a Study By the Spanish Group of Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 4331-4331.	0.6	0
77	Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. <i>Leukemia</i> , 2015, 29, 1875-1881.	3.3	93
78	Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 389-396.	0.1	3
79	Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. <i>Leukemia Research</i> , 2015, 39, 52-57.	0.4	18
80	Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. <i>Bone Marrow Transplantation</i> , 2015, 50, 579-584.	1.3	49
81	CVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 121-126.	1.3	8
82	Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. <i>Lancet Haematology,the</i> , 2015, 2, e260-e266.	2.2	24
83	Few and Nonsevere Adverse Infusion Events Using an Automated Method for Diluting and Washing before Unrelated Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 682-687.	2.0	7
84	Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. <i>Brain</i> , 2015, 138, 2847-2858.	3.7	128
85	Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. <i>Journal of Geriatric Oncology</i> , 2015, 6, 353-361.	0.5	51
86	Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1371-1374.	1.3	4
87	Post-Thaw Viable CD45 + Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in Adult Patients with Malignant Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2167-2172.	2.0	17
88	Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2812-2818.	0.6	5
89	Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time. <i>Bone Marrow Transplantation</i> , 2015, 50, 274-281.	1.3	18
90	Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. <i>Blood</i> , 2015, 126, 2861-2861.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?. PLoS ONE, 2015, 10, e0129375.	1.1	19
92	Mutational Studies Using Next Generation Sequencing in High Risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Patients Treated with Azacitidine (High risk MDS 2009 protocol) Tj ETQq0 0 0 0 BT /Overdock 10 Tf		
93	Optimization of health-care organization and perceived improvement of patient comfort by switching from intra-venous BU four-times-daily infusions to a once-daily administration scheme in adult hematopoietic stem cell recipients. Bone Marrow Transplantation, 2014, 49, 509-512.	1.3	1
94	Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. Mediators of Inflammation, 2014, 2014, 1-7.	1.4	16
95	Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica, 2014, 99, 1632-1637.	1.7	26
96	Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. British Journal of Haematology, 2014, 166, 189-201.	1.2	15
97	A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low-or intermediate-risk myelodysplastic syndrome. American Journal of Hematology, 2014, 89, E156-62.	2.0	20
98	Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 1418-1425.	2.0	40
99	Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 66-72.	2.0	41
100	IMPACT of Therapeutic Strategy and Time to Therapy Initiation on Clinical Evolution in Higher-Risk Myelodysplastic Syndromes. a Report from Erasme Study. Blood, 2014, 124, 1908-1908.	0.6	2
101	Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome. Blood, 2014, 124, 1165-1165.	0.6	0
102	IMPACT of Therapeutic Strategy and Time to Therapy Initiation on Clinical Evolution of Patients with NEWLY Diagnosed Chronic Myelomonocytic Leukemia. a Report from Erasme Study. Blood, 2014, 124, 5607-5607.	0.6	0
103	Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome. Blood, 2014, 124, 4649-4649.	0.6	0
104	Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. Leukemia Research, 2013, 37, 769-776.	0.4	11
105	5q- syndrome and multiple myeloma diagnosed simultaneously and successfully treated with lenalidomide. Leukemia Research, 2013, 37, 1248-1250.	0.4	8
106	Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1387-1392.	2.0	24
107	Impact of Hyperferritinemia on the Outcome of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies. Biology of Blood and Marrow Transplantation, 2013, 19, 597-601.	2.0	6
108	Updated Experience with Inolimomab as Treatment for Corticosteroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 435-439.	2.0	11

#	ARTICLE	IF	CITATIONS
109	Complex, Not Monosomal, Karyotype Is the Cytogenetic Marker of Poorest Prognosis in Patients With Primary Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2013, 31, 916-922.	0.8	65
110	Primary gastrointestinal aspergillosis 6Âmonths after allogeneic hematopoietic cell transplantation: a case report. <i>Transplant Infectious Disease</i> , 2013, 15, E107-10.	0.7	2
111	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. <i>Blood</i> , 2013, 121, 3005-3015.	0.6	251
112	The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycophenolate. <i>Haematologica</i> , 2013, 98, 526-532.	1.7	30
113	Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score. <i>Blood</i> , 2013, 122, 2754-2754.	0.6	0
114	Rituximab treatment may disturb the normal pattern of lymphopoiesis after cord blood SCT. <i>Bone Marrow Transplantation</i> , 2012, 47, 458-460.	1.3	1
115	Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2012, 97, 310-317.	1.7	194
116	Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. <i>Bone Marrow Transplantation</i> , 2012, 47, 1343-1349.	1.3	13
117	Evaluation of prognostic factors among patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2012, 97, 1187-1195.	1.7	15
118	Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1716-1726.	2.0	55
119	Degree of mucositis and duration of neutropenia are the major risk factors for early postâ€transplant febrile neutropenia and severe bacterial infections after reducedâ€intensity conditioning. <i>European Journal of Haematology</i> , 2012, 88, 46-51.	1.1	20
120	A scoring system to predict the risk of death during induction with anthracycline plus cytarabineâ€based chemotherapy in patients with de novo acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 410-417.	2.0	24
121	Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome. <i>American Journal of Hematology</i> , 2012, 87, 9-14.	2.0	23
122	One-Antigen Mismatched Related versus HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia: Center for International Blood and Marrow Transplant Research Results in the Era of Molecular HLA Typing. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 640-648.	2.0	55
123	Pretransplantation Liver Function Impacts on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Study of 455 Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1653-1661.	2.0	17
124	Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. <i>Haematologica</i> , 2011, 96, 1072-1076.	1.7	155
125	Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. <i>Bone Marrow Transplantation</i> , 2011, 46, 330-337.	1.3	104
126	Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. <i>Bone Marrow Transplantation</i> , 2011, 46, 690-701.	1.3	18

#	ARTICLE	IF	CITATIONS
127	Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. <i>Bone Marrow Transplantation</i> , 2010, 45, 534-542.	1.3	32
128	MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. <i>Bone Marrow Transplantation</i> , 2010, 45, 1449-1456.	1.3	43
129	Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk Groups: The Flexible HCT-CI Is the Best Predictor of NRM and OS in a Population of Patients Undergoing allo-RIC. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 413-420.	2.0	67
130	Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 957-966.	2.0	35
131	Hepatic Toxicity After Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation: Incidence, Characteristics and Risk Factors In a Cohort of 452 Patients.. <i>Blood</i> , 2010, 116, 3495-3495.	0.6	0
132	Beta ₂ -microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. <i>British Journal of Haematology</i> , 2009, 145, 801-805.	1.2	41
133	Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009, 44, 749-756.	1.3	51
134	Study of Kidney Function Impairment after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 21-29.	2.0	53
135	Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 639-642.	2.0	45
136	Early and Late Neurological Complications after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1439-1446.	2.0	79
137	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. <i>Lancet Oncology</i> , The, 2009, 10, 855-864.	5.1	620
138	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen. <i>Cytotherapy</i> , 2009, 11, 356-361.	0.3	4
139	Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease. <i>Current Opinion in Oncology</i> , 2009, 21, S35-S37.	1.1	6
140	Comparative pharmacodynamic time-course of bempiparin and enoxaparin in healthy volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2009, 47, 726-732.	0.3	7
141	Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. <i>Bone Marrow Transplantation</i> , 2008, 41, 33-38.	1.3	60
142	Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2008, 41, 425-437.	1.3	14
143	Reduced-Intensity Conditioning Allogeneic Transplantation from Unrelated Donors: Evaluation of Mycophenolate Mofetil Plus Cyclosporin A as Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 664-671.	2.0	25
144	Prospective Oral Mucositis Audit: Oral Mucositis in Patients Receiving High-Dose Melphalan or BEAM Conditioning Chemotherapyâ€”European Blood and Marrow Transplantation Mucositis Advisory Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1519-1525.	0.8	155

#	ARTICLE	IF	CITATIONS
145	Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 577-584.	0.8	213
146	Treatment of Chronic Myeloid Leukemia with Imatinib. A Single Centre Experience. <i>Blood</i> , 2008, 112, 4289-4289.	0.6	0
147	One Antigen HLA-Mismatched Related and 8/8 Allele Matched Unrelated Donors Are Associated with Similar Survival after Hematopoietic Cell Transplantation for Acute Leukemia.. <i>Blood</i> , 2008, 112, 965-965.	0.6	7
148	Targeting the Poor Mobilizing Population of Patients for An Autologous Transplantation Procedure: A Single Centre Experience. <i>Blood</i> , 2008, 112, 4136-4136.	0.6	0
149	Cyclosporine a and Mycophenolate Mofetil Vs Cyclosporine a and Methotrexate as Gvhd Prophylaxis in Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donor.. <i>Blood</i> , 2008, 112, 2229-2229.	0.6	0
150	Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. <i>Current Opinion in Oncology</i> , 2007, 19, 660-666.	1.1	15
151	370: Fludarabine-busulphan reduced intensity conditioning (RIC) identical sibling allogeneic stem cell transplantation (allo-SCT) in high risk acute myeloid leukemia and myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 134-135.	2.0	1
152	Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Using Oral Fludarabine as Part of the Conditioning Regimen.. <i>Blood</i> , 2007, 110, 4925-4925.	0.6	0
153	Encouraging Results with Inolimomab (Anti-IL-2 Receptor) as Treatment for Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1135-1141.	2.0	30
154	The effect of immunoglobulinVH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2006, 107, 1023-1033.	2.0	82
155	Fludarabine and Busuphan (Flu-Bu) as Reduced Intensity-Conditioning (RIC) Regimen in HLA-Identical Sibling Allogeneic Hematopoietic Stem Transplantation (Allo-SCT) for Myeloid Malignancies. Results of a Prospective Multicenter Study.. <i>Blood</i> , 2006, 108, 5363-5363.	0.6	0
156	Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. <i>British Journal of Haematology</i> , 2005, 130, 394-403.	1.2	110
157	Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. <i>European Journal of Haematology</i> , 2005, 74, 144-151.	1.1	68
158	Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. <i>Bone Marrow Transplantation</i> , 2003, 31, 387-392.	1.3	73
159	Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. <i>Haematologica</i> , 2003, 88, 300-5.	1.7	20
160	Mouth-washings with recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. <i>Bone Marrow Transplantation</i> , 2002, 29, 783-787.	1.3	31
161	Measuring the Capacitance of a Lossy Detector. <i>Measurement Techniques</i> , 2002, 45, 875-878.	0.2	0